The United States Patent and Trademark Office has issued a patent for Lorus Therapeutics' LOR-253, which covers composition of matter and methods of treating cancer. The patent was initially set to expire in May 2026 and latter was ...
Lorus Therapeutics has received first Japanese patent for its small molecule anticancer drug LOR-253 that will provide Lorus with exclusive rights to LOR-253 in Japan until 2023. The patent will provide protection for LOR-253 composition ...